A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro with an Open-Label Postprandial LY900014 Treatment Group, in Combination with Insulin Glargine or Insulin Degludec, in Adults with Type 1 Diabetes
Phase of Trial: Phase III
Latest Information Update: 09 Apr 2018
At a glance
- Drugs Insulin lispro (Primary) ; Insulin degludec; Insulin glargine
- Indications Type 1 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms PRONTO-T1D
- Sponsors Eli Lilly
- 19 Jul 2017 Status changed from not yet recruiting to recruiting.
- 14 Jul 2017 Planned number of patients changed from 1328 to 1567.
- 05 Jun 2017 New trial record